NR4A1 and breast carcinoma: In human breast cancer therapies, endocrine therapy is added to chemotherapy in hormone receptor–positive subtypes; the c-erbB-2 overexpressing subtype is c-erbB-2 driven and appropriate for chemotherapy and c-erbB-2 targeted therapy such as trastuzumab.